Evidence map›Paper›PMID 38596495›Full record

ArticleWorld journal of gastroenterology2024

Vonoprazan-amoxicillin dual regimen with

Valerie Josephine Dirjayanto, Jessica Audrey, Daniel Martin Simadibrata

Open access · hybridAbstract readEditorial
In one paragraph

Article in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Valerie Josephine DirjayantoFaculty of Medicine, Universitas Indonesia, Jakarta Pusat 10430, DKI Jakarta, Indonesia.
Jessica AudreyFaculty of Medicine, Universitas Indonesia, Jakarta Pusat 10430, DKI Jakarta, Indonesia.
Daniel Martin SimadibrataDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, United States.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Yu

Indexed as

Helicobacter InfectionsHelicobacter pyloriPyrrolesSaccharomyces boulardiiSulfonamidesAmoxicillinAnti-Bacterial AgentsClarithromycinDrug Therapy, CombinationH(+)-K(+)-Exchanging ATPaseHumansIonsProton Pump InhibitorsTreatment Outcome1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineAmoxicillinAnti-Bacterial AgentsClarithromycinH(+)-K(+)-Exchanging ATPaseIonsProton Pump InhibitorsPyrrolesSulfonamidesEradication rateHelicobacter pyloriRescue therapySaccharomyces boulardiiVonoprazan

Identifiers

PMID38596495
PMCPMC11000074
OpenAlexW4392805954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.